01 Reference 1-Safety Communications _ Chronic Cerebrospinal Venous Insufficiency…

Other agency documents in this docket

• FDA-2012-P-0119-0021Mario Morais Email March 15 2017
• FDA-2012-P-0119-001705 Reference 3-PDUFA _ Enhancing Benefit-Risk Assessment in Regulatory Decision-Making
• FDA-2012-P-0119-001806 Reference 4-Fed Register PDUFA Patient-focused Drug Development - Request for Comments
• FDA-2012-P-0119-001402 Guidance for Industry 1-Expanded Access to Investigational Drugs for Treatment Use —…
• FDA-2012-P-0119-001503 Guidance for Industry 2-Individual Patient Expanded Access Applications_ Form FDA 3926
• FDA-2012-P-0119-001604 - Reference 2-PDUFA _ The Voice of the Patient_ A Series of Reports from FDA's…
• FDA-2012-P-0119-0011FDA Response to joint appeal in FDA-2012-P-0119 and FDA-2013-P-0735
• FDA-2012-P-0119-0012Reference List for 0119
• FDA-2012-P-0119-001907 Reference 5-Prescription Drug User Fee Act (PDUFA) _ Patient-Focused Drug Development_…
• FDA-2012-P-0119-002008 Reference 6-PDUFA Reauthorization Performance Goals and Procedures FY18-22